ScienceDaily Logo
Text Size >  A  A  A  



Infectious Disease
More on Infectious Disease
Spotlight

Focus On: Dalbavancin A novel long-acting lipoglycopeptide antibiotic

Dalbavancin (Pfizer) is a new lipoglycopeptide antibiotic in phase 3 trials for the treatment of resistant gram-positive pathogens including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE). This agent exerts its bactericidal activity by binding to the terminal D-alanyl-D-alanine moiety of peptidoglycan precursors, thus blocking enzymes involved in the final stages of peptidoglycan synthesis and cell wall formation. Peak concentrations of dalbavancin occur immediately following infusion and increase in proportion to the dose given.
  More>>
TOPIC AREAS
 
   
 
Search



Popular Search Terms
 
Featured Wire Releases What's this?
11-6-07 17:32 ET
New Physician Resource for Practice Management, Clinical Decision Support and Patient Care
Features

ICAAC homes in on recurrent infections

New antimicrobials, the increased pathogenicity and emergence of hyper-toxin-producing strains of Clostridium difficile, and new ways to treat recurrent genital herpes were some of the issues addressed at the recent 45th annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), held recently in Washington, D.C.
  More>>


New biologic helps those with PI help themselves

Until now, patients with primary immunodeficiency (PI) were treated with intravenous immunoglobulin (IVIg) infusions, which were inconvenient and associated with serious adverse side effects, such as migraine headaches.
  More>>


Influence of a UTI empiric treatment pathway on physician prescribing in an academic medical center

In an attempt to improve patient outcomes and control costs, a guide to empiric antimicrobial therapy, including a urinary tract infection (UTI) algorithm, was distributed to hospital physicians at an academic medical center. A retrospective study was conducted to assess the impact of the guide on physician prescribing of empiric antimicrobial therapy for UTIs.
  More>>


Some spelling "B" ! A boy, his brother, and their "bug"

Your patient is a 5-year-old boy who has a fever and is complaining of left flank pain. He looks flushed and is slightly diaphoretic.
  More>>
Industry Roundup

New treatments target infectious diseases

 


Bacterial update

 


CDC updates hepatitis B vaccine recommendations

 


Tiny, tropical sand fly can spell big trouble

 
Wire Releases What's this?
November 2007
 
11-6-07 17:32 ET

New Physician Resource for Practice Management, Clinical Decision Support and Patient Care

August 2006
 
8-24-06 12:03 ET

2005 Medical Group Data Finds Financial Losses, Despite Increases in Physician Compensation for Most Specialties

April 2006
 
4-27-06 14:45 ET

Pharmacy Benefit Management Institute Recognizes Innovation in Drug Benefit Industry

March 2006
 
3-29-06 16:23 ET

MerckMedicus™ Provides Online and Wireless Access to Medical Resources With No Access Fees

3-23-06 8:52 ET
Skyscape Launches Harriet Lane Handbook With Exclusive New Tools For Point of Care Decision-Support -- Featured at NAPNAP, booth #1213 --

3-13-06 11:13 ET
CME² Launches Seizure Disorders in the Elderly: Recognition, Diagnosis, and Treatment CME/CE Program
More Wire Releases
Related Topic Area

> HIV & AIDS

 
A new resource for time-starved physicians and healthcare professionals
Modern Medicine - Click Here


Privacy Policy Disclaimer Copyright Editorial Policy Sponsorship Policy All Topics
   Powered by Mediwire
 
Can't find it? Try searching ScienceDaily or the entire web with:
Google
  Web sciencedaily.com
 
 Search Our Archives
Find:
in:
from:
to
sort:
relevance date
 
 New Job Postings
Find:
City:
State:
View:
Post:

 

———————   Copyright © 1995-2005 ScienceDaily LLC   |   Contact: editor@sciencedaily.com   ———————